Coloplast A/S (CLPBY)
12.56
+0.20
(+1.62%)
USD |
OTCM |
May 17, 16:00
Coloplast Revenue (Quarterly): 959.30M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 959.30M |
| December 31, 2023 | 953.39M |
| September 30, 2023 | 909.21M |
| June 30, 2023 | 892.71M |
| March 31, 2023 | 874.08M |
| December 31, 2022 | 839.26M |
| September 30, 2022 | 820.29M |
| June 30, 2022 | 837.34M |
| March 31, 2022 | 829.99M |
| December 31, 2021 | 795.05M |
| September 30, 2021 | 808.56M |
| June 30, 2021 | 783.57M |
| March 31, 2021 | 770.50M |
| December 31, 2020 | 758.97M |
| September 30, 2020 | 721.06M |
| June 30, 2020 | 652.60M |
| March 31, 2020 | 712.02M |
| December 31, 2019 | 698.53M |
| September 30, 2019 | 687.93M |
| June 30, 2019 | 691.90M |
| March 31, 2019 | 669.80M |
| December 31, 2018 | 660.60M |
| September 30, 2018 | 660.26M |
| June 30, 2018 | 676.98M |
| March 31, 2018 | 665.67M |
| Date | Value |
|---|---|
| December 31, 2017 | 625.80M |
| September 30, 2017 | 628.98M |
| June 30, 2017 | 578.43M |
| March 31, 2017 | 555.99M |
| December 31, 2016 | 544.48M |
| September 30, 2016 | 560.65M |
| June 30, 2016 | 559.59M |
| March 31, 2016 | 532.26M |
| December 31, 2015 | 536.14M |
| September 30, 2015 | 539.25M |
| June 30, 2015 | 524.16M |
| March 31, 2015 | 522.09M |
| December 31, 2014 | 553.92M |
| September 30, 2014 | 571.51M |
| June 30, 2014 | 575.93M |
| March 31, 2014 | 553.84M |
| December 31, 2013 | 558.93M |
| September 30, 2013 | 527.81M |
| June 30, 2013 | 518.17M |
| March 31, 2013 | 502.95M |
| December 31, 2012 | 498.18M |
| September 30, 2012 | 478.29M |
| June 30, 2012 | 488.32M |
| March 31, 2012 | 474.68M |
| December 31, 2011 | 480.55M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
652.60M
Minimum
Jun 2020
959.30M
Maximum
Mar 2024
799.81M
Average
801.80M
Median
Revenue (Quarterly) Benchmarks
| Genmab A/S | 603.46M |
| Ascendis Pharma A/S | 104.16M |
| Galecto Inc | -- |
| Evaxion Biotech AS | 0.073M |
| IO Biotech Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 182.36M |
| Total Expenses (Quarterly) | 698.43M |
| EPS Diluted (Quarterly) | 0.0811 |
| Enterprise Value | 31.53B |
| Gross Profit Margin (Quarterly) | 67.98% |
| Profit Margin (Quarterly) | 19.01% |
| Earnings Yield | 2.60% |
| Operating Earnings Yield | 3.69% |
| Normalized Earnings Yield | 2.588 |